← Back to Screener
Instil Bio, Inc. Common Stock (TIL)
Price$8.07
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-44.68%
Price vs S&P 500 (4W)-1.09%
VGM Score35.31
Market Capitalization$54.73M
All Metrics
Book Value / Share (Quarterly)$16.32
P/TBV (Annual)0.22x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-6.45
Price vs S&P 500 (YTD)-34.79%
EPS (TTM)$-7.08
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$-7.08
EPS (Annual)$-11.37
ROI (Annual)-29.18%
Cash / Share (Quarterly)$11.00
ROA (Last FY)-28.08%
EBITD / Share (TTM)$-8.17
ROE (5Y Avg)-43.06%
Cash Flow / Share (Annual)$-6.87
P/B Ratio0.49x
P/B Ratio (Quarterly)0.50x
Net Income / Employee (Annual)$-4,352,900
Net Interest Coverage (TTM)-129.63x
ROA (TTM)-22.38%
EPS Incl Extra (Annual)$-11.37
Current Ratio (Annual)39.53x
Quick Ratio (Quarterly)39.59x
3-Month Avg Trading Volume0.04M
52-Week Price Return-73.39%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.79
P/S Ratio (Annual)390.93x
Asset Turnover (Annual)0.00x
52-Week High$42.79
EPS Excl Extra (Annual)$-11.37
CapEx CAGR (5Y)-27.76%
26-Week Price Return-36.76%
Quick Ratio (Annual)39.11x
13-Week Price Return-5.61%
Total Debt / Equity (Annual)0.74x
Current Ratio (Quarterly)39.87x
Enterprise Value$134.71M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-26850.00%
Cash / Share (Annual)$11.23
3-Month Return Std Dev36.45%
Net Income / Employee (TTM)$-2,786,800
ROE (Last FY)-43.67%
Net Interest Coverage (Annual)-20.08x
EPS Basic Excl Extra (Annual)$-11.37
Total Debt / Equity (Quarterly)0.77x
EPS Incl Extra (TTM)$-7.08
ROI (TTM)-23.24%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.79
Price vs S&P 500 (52W)-97.76%
Year-to-Date Return-26.64%
5-Day Price Return-0.49%
EPS Normalized (Annual)$-11.37
ROA (5Y Avg)-31.97%
Net Profit Margin (Annual)-26957.14%
Month-to-Date Return0.00%
Cash Flow / Share (TTM)$-1.44
EBITD / Share (Annual)$-10.81
Operating Margin (Annual)-24028.57%
LT Debt / Equity (Annual)0.74x
ROI (5Y Avg)-34.46%
LT Debt / Equity (Quarterly)0.77x
EPS Basic Excl Extra (TTM)$-7.08
P/TBV (Quarterly)0.22x
P/B Ratio (Annual)0.66x
Book Value / Share (Annual)$16.79
Price vs S&P 500 (13W)-13.87%
Beta1.88x
Revenue / Share (TTM)$0.00
ROE (TTM)-39.76%
52-Week Low$5.67
mGradeD
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.62est. -0.60
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.88
3.88
4.00
4.00
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TILInstil Bio, Inc. Common Stock | — | — | D | $8.07 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Instil Bio is a clinical-stage biopharmaceutical company developing cell therapy treatments for cancer using tumor infiltrating lymphocytes (TILs). The company's proprietary CoStAR platform enables genetic engineering of TILs to enhance their recognition of tumor-associated antigens. Its lead candidate, ITIL-306, is in clinical development for multiple solid tumors including ovarian, uterine, non-small cell lung cancer, and renal cancer.